Diffusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DFFN)

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Diffusion Pharmaceuticals's stock reverse split on the morning of Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.69) by $0.06. View Diffusion Pharmaceuticals' Earnings History.

Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Diffusion Pharmaceuticals.

1 Wall Street analysts have issued twelve-month price targets for Diffusion Pharmaceuticals' shares. Their predictions range from $10.00 to $10.00. On average, they anticipate Diffusion Pharmaceuticals' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.

Media coverage about DFFN stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totalling 80,300 shares, a decline of 19.9% from the August 30th total of 100,200 shares. Based on an average trading volume of 65,100 shares, the short-interest ratio is presently 1.2 days. Currently, 1.8% of the shares of the stock are short sold. View Diffusion Pharmaceuticals' Current Options Chain.

Some companies that are related to Diffusion Pharmaceuticals include ContraFect (CFRX), Alimera Sciences (ALIM), Sierra Oncology (SRRA), Intec Pharma (NTEC), Provectus Biopharmaceuticals (PVCT), Ceapro (CRPOF), Mateon Therapeutics (MATN), Acerus Pharmaceuticals (TRLPF), OncoSec Medical (ONCS), ProPhase Labs (PRPH), Aytu Bioscience (AYTU), Pain Therapeutics (PTIE), Cassava Sciences (SAVA), AzurRx BioPharma (AZRX) and RegeneRx Biopharmaceuticals (RGRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Coherus Biosciences (CHRS), Intercept Pharmaceuticals (ICPT), Verastem (VSTM), Agile Therapeutics (AGRX), Achaogen (AKAO), Fibrocell Science (FCSC), Lipocine (LPCN) and MEI Pharma (MEIP).

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DFFN stock can currently be purchased for approximately $1.35.

Diffusion Pharmaceuticals has a market capitalization of $6.33 million. The company earns $-18,370,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe.View Additional Information About Diffusion Pharmaceuticals.

The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com/.

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]